This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Shigehisa Nagahashi: Innovator in Monoclonal Antibody Research
Introduction
Shigehisa Nagahashi is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for cancer treatment and angiogenesis inhibition.
Latest Patents
Nagahashi holds a patent for a monoclonal antibody capable of binding to anexelekto. This invention is notable for its specific functions, including an angiogenesis-suppressive effect and an antitumor effect. The anti-AXL antibodies developed by Nagahashi and his team are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity. He has 1 patent to his name.
Career Highlights
Shigehisa Nagahashi is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at Chugai has allowed him to focus on innovative research that addresses critical health challenges.
Collaborations
Nagahashi has collaborated with notable colleagues, including Takehisa Kitazawa and Tsukasa Suzuki. These partnerships have enhanced the research and development of effective therapeutic agents.
Conclusion
Shigehisa Nagahashi's contributions to monoclonal antibody research exemplify the impact of innovation in biotechnology. His work continues to pave the way for advancements in cancer treatment and therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile